§ 4258. Overdose prevention; drug-checking for contaminant detection
(a) Notwithstanding any other provision of law, it shall not be a violation of this chapter
for an approved drug-checking service provider to receive, possess, transport, or
store samples of a substance that may contain a regulated drug solely for purposes
of analyzing the substance to determine its chemical composition and disseminate information
regarding the analysis to the provider of the substance.
(b) On-site approved drug-checking service providers shall be permitted to:
(1) collect voluntarily provided residual samples of substances potentially containing
regulated drugs, possess, transport, or store samples of a regulated drug solely for
purposes of analyzing the substances to determine its chemical composition as a lifesaving
intervention;
(2) use any available technologies to analyze the contents of samples to obtain timely,
highly accurate information regarding the composition of drugs to prevent overdose
and mitigate health risks;
(3) provide results of analysis obtained from drug-checking technology to the person requesting
drug services;
(4) disseminate data containing only the results of analysis and containing no personally
identifiable information to community members at risk of overdose; and
(5) if necessary, arrange for a sample of a drug or substance to be tested by an approved
laboratory.
(c) In operating any drug-checking service, personally identifiable information may be
collected from a person providing a controlled substance to an approved drug-checking
service provider only as necessary to communicate drug-checking results to the person.
Personally identifiable information collected solely for the purposes of communicating
drug-checking results shall not be retained or shared by an approved drug-checking
service provider.
(d) An employee, contractor, volunteer, or other person acting in the good faith provision
of drug-checking services and acting in accordance with established protocols shall
not:
(1) be subject to arrest, charge, or prosecution for a violation pursuant to this chapter,
including for attempting to, aiding and abetting in, or conspiracy to commit a violation
of this chapter;
(2) have their property subject to forfeiture, any civil or administrative penalty, or
liability of any kind, including disciplinary action by a professional licensing board,
credentialing restrictions, contractual or civil liability, or medical staff or other
employment action; or
(3) be denied any right or privilege for actions, conduct, or omissions relating to the
operation of a drug-checking service in compliance with this chapter and any rules
adopted pursuant to this chapter.
(e) An individual possessing a regulated substance and who provides any portion of the
substance to an approved drug-checking service provider pursuant to this section for
purposes of obtaining drug-checking services shall not be subject to arrest, charge,
or prosecution for possession of a regulated substance pursuant to this chapter or
civil or administrative penalty or disciplinary action by a professional licensing
board for a violation of this chapter based on the individual’s use or attempted use
of drug-checking services in accordance with this section. The immunity provisions
of this subsection shall apply only to the use and derivative use of evidence gained
as a proximate result of an individual seeking drug-checking services and shall not
preclude prosecution of the individual on the basis of evidence obtained from an independent
source.
(f) Local governments shall not collect, maintain, use, or disclose any personal information
relating to an individual from whom local government receives any drug or substance
for checking or disposal.
(g) The result of a test carried out by an approved drug-checking service provider shall
not be admissible as evidence in any criminal or civil proceeding.
(h)(1) The Department shall provide technical assistance to and develop operating guidelines
for drug-checking service providers.
(2) The Department shall coordinate the collection and dissemination of deidentified data
related to drug-checking services to inform prevention and public health initiatives. (Added 2023, No. 22, § 12, eff. May 25, 2023; renumbered from 18 V.S.A. § 4240a by 2023, No. 178 (Adj. Sess.), § 8, eff. June 17, 2024.)